» Articles » PMID: 35976316

How I Treat Parkinson's Disease

Overview
Publisher Thieme
Specialties Neurology
Psychiatry
Date 2022 Aug 17
PMID 35976316
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Parkinson's disease (PD) is a complex neurodegenerative condition. Treatment strategies through all stages of disease progression could affect quality of life and influence the development of future complications, making it crucial for the clinician to be on top of the literature.

Objective: This paper reviews the current treatment of PD, from early to advanced stages.

Methods: A literature review was conducted focusing on the treatment of PD, in the different stages of progression.

Results: Every individual with a new diagnosis of PD should be encouraged to start exercising regularly. In the early stage, treatment should focus on using the lowest dose of levodopa or combination therapy that provides maximum functional capacity, and does not increase the risk of complications, such as peak dose dyskinesias and impulse control disorders. At the moderate and advanced stages, motor fluctuations and complications of treatment dominate the picture, making quality of life one important issue. Rehabilitation programs can improve motor symptoms and should be offered to all patients at any stage of disease progression.

Conclusion: Many factors need to be considered when deciding on the best treatment strategy for PD, such as disease progression, presence of risk factors for motor and behavioral complications, potential side effects from dopaminergic therapy and phenotypical variabilities. Treatment should focus on functional capacity and quality of life throughout the whole disease course.

Citing Articles

Correlation between motor function and health-related quality of life in early to mid-stage patients with Parkinson disease: a cross-sectional observational study.

Ge Y, Zhao W, Zhang L, Zhao X, Shu X, Li J Front Aging Neurosci. 2024; 16:1399285.

PMID: 38979112 PMC: 11228142. DOI: 10.3389/fnagi.2024.1399285.


Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.

Isaacson S, Hauser R, Pahwa R, Gray D, Duvvuri S Clin Park Relat Disord. 2023; 9:100212.

PMID: 37497384 PMC: 10366643. DOI: 10.1016/j.prdoa.2023.100212.

References
1.
Verschuur C, Suwijn S, Boel J, Post B, Bloem B, van Hilten J . Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. N Engl J Med. 2019; 380(4):315-324. DOI: 10.1056/NEJMoa1809983. View

2.
Barbosa A, Chen J, Freitag F, Valente D, Souza C, Voos M . Gait, posture and cognition in Parkinson's disease. Dement Neuropsychol. 2017; 10(4):280-286. PMC: 5619266. DOI: 10.1590/s1980-5764-2016dn1004005. View

3.
Jankovic J, Tan E . Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020; 91(8):795-808. DOI: 10.1136/jnnp-2019-322338. View

4.
Rajput A . Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord. 2001; 8(2):95-100. DOI: 10.1016/s1353-8020(01)00023-2. View

5.
Hauser R, Schapira A, Rascol O, Barone P, Mizuno Y, Salin L . Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord. 2010; 25(15):2542-9. DOI: 10.1002/mds.23317. View